Georges Siotis, Carmine Ornaghi, Micael Castanheira, 28 February 2021

A perplexing feature surrounding generic entry is that the price of the other on-patent potential substitutes is barelyaffected, leading competition authorities to conclude sometimes that a single molecule may constitute a distinct antitrust market.  Using data on prices, quantities, and promotional effort for a large number of molecules sold in the US, this column finds that there is no such thing as a single/natural antitrust market, even for a fixed set of products (and absent technological, regulatory, or trade shocks).  

Events

CEPR Policy Research